Jennison Associates
RYTM icon

Jennison Associates’s Rhythm Pharmaceuticals RYTM Stock Holding History

Jennison Associates’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-918,567
Closed -$98.3M – 626
2025
Q4 		$98.3M Buy
918,567
+507,017
+123% +$53.8M 0.06% 137
2025
Q3 		$41.6M Buy
+411,550
New +$38.2M 0.02% 247

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Jennison Associates's RYTM Position: Q1 2026 in Review

Jennison Associates sold out of Rhythm Pharmaceuticals (RYTM) in Q1 2026, closing a stake of 918,567 shares — an estimated $98.3M sold.

Jennison Associates first reported a position in RYTM in Q3 2025 and held it in 2 quarters. The position peaked at $98.3M in Q4 2025. 285 funds tracked by Wall St. Rank hold RYTM as of Q1 2026.

  • Jennison Associates reported no remaining Rhythm Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Jennison Associates sold 918,567 Rhythm Pharmaceuticals shares in Q1 2026, an estimated $98.3M.
  • Jennison Associates first reported a position in Rhythm Pharmaceuticals in Q3 2025 and held it in 2 quarters.
  • Jennison Associates's Rhythm Pharmaceuticals position peaked at $98.3M in Q4 2025.
  • 285 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q1 2026.

Based on Jennison Associates's 13F filing for Q1 2026, filed 6 May 2026.